Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q5VVY1

UPID:
NTM1B_HUMAN

ALTERNATIVE NAMES:
Alpha N-terminal protein methyltransferase 1B; Methyltransferase-like protein 11B; X-Pro-Lys N-terminal protein methyltransferase 1B

ALTERNATIVE UPACC:
Q5VVY1; B2RXI0

BACKGROUND:
The enzyme Methyltransferase-like protein 11B, known for its specificity in methylating the N-terminus of target proteins, is integral to cellular regulation and signaling. By catalyzing the addition of methyl groups to the N-terminal motif [Ala/Pro/Ser]-Pro-Lys, it influences protein interactions and functionality. Its ability to activate NTMT1 by priming substrates for trimethylation further highlights its critical role in the methylation cascade.

THERAPEUTIC SIGNIFICANCE:
Exploring the enzymatic pathways of Methyltransferase-like protein 11B unveils potential avenues for therapeutic intervention. Its central role in protein methylation presents opportunities for developing novel treatments, emphasizing the importance of research in this area for advancing medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.